Introduction
Acute myeloid leukemia (AML) accounts for approximately 20% of acute leukemias in children. Significant progress in improving outcome for AML patients has been achieved over the last two decades and is mainly attributed to intensification of chemotherapy. For example, the introduction of high-dose cytarabine and mitoxantrone significantly increased the 5-year eventfree survival of high-risk patients treated according to the clinical trial AML-BFM 93 compared with the previous trial AML-BFM 87 (44 vs 31%; P ¼ 0.01). 1 Intensive chemotherapy, however, also increased the risk of infectious complications, which are a substantial cause of morbidity and mortality in this patient population. 2 Recently, the clinical trial CCG-2961 was suspended because of a high number of therapy-related toxic deaths (Feusner et al. Blood 2002 ; 100: 332a; abstract). Surprisingly, published data about the incidence and characteristics of infectious complications in patients undergoing therapy for AML are limited. 3, 4 This prompted us to perform a retrospective study in children undergoing therapy for AML according to the multi-institutional clinical trial AML-BFM 93.
The objectives of this study were to identify the incidence, main pathogens and sites, as well as risk factors of infectious complications. The results of this analysis may help to improve supportive care strategies in patients undergoing therapy for AML, to decrease morbidity and mortality, and thus, to improve overall survival.
Patients and methods
The medical records of 304 patients enrolled in the prospective multi-institutional clinical trial AML-BFM 93 were reviewed. These 304 patients consisted of 276 patients officially enrolled as protocol patients, and 28 patients with Down syndrome who were not registered as protocol patients, but were treated according to AML-BFM 93 and were therefore subjects of this retrospective report. All data regarding infectious complications occurring during intensive treatment were gathered by two of the authors (DV and JK) in the hospital where the patient had been treated. Infectious complications were defined as fever requiring antibiotic therapy and/or clinical signs and symptoms associated with the isolation of a pathogen or an identifiable site of infection by physical examination or imaging study. One cycle of chemotherapy was defined as the time from the start of chemotherapy (eg induction therapy) until the day before the start of the next cycle of chemotherapy (eg consolidation). Fever was documented if one axillary temperature was greater than 38.51C or two measurements of 38-38.51C were taken within a 4-h interval. Neutropenia was defined as an absolute neutrophil count p500/ml. Infectious episodes were categorized as microbiologically or clinically documented infections or as fever without an identifiable source (FUO). Bacteremia was defined as fever with a positive blood culture for bacteria (peripheral blood or from the central venous indwelling catheter). If the bloodstream isolate was a potential skin contaminant (eg coagulase-negative staphylococci (CoNS), Propionibacterium spp, Bacillus spp), the presence of an intravascular catheter was required for the diagnosis of a bloodstream infection. 5 The diagnosis of infection of the gastrointestinal (GI) tract was made when clinical symptoms could be attributed to a pathogen (such as Clostridium difficile or rotavirus). Diarrhea alone or the recovery of a pathogen in the stool without clinical symptoms did not fulfill the criteria of GI tract infection. Similarly, the diagnosis of pneumonia was based on pathological chest X-ray and/or CT scan accompanied by clinical symptoms of lower respiratory infection. The diagnosis of an infection of the central venous line (CVL) was only made when a pathogen could be isolated from the tip of the CVL or from the insertion site combined with clinical symptoms such as erythema and/or exudate. Fungal infection were defined as proven invasive infection (positive histopathologic findings or positive culture) or probable invasive infection (at least one host factor criterion, such as neutropenia for more than 10 days or persistent fever refractory to broad-spectrum antibacterial treatment in high-risk patients; and one microbiological criterion, such as a positive result of culture for Aspergillus spp from sputum or brochoalveolar lavage fluid samples or a positive result for Aspergillus antigen in at least two blood samples; and one major (or two minor) clinical criterion such as halo-sign or air crescent sign on pulmonary CT imaging), according to criteria published recently. 6 Nearly all patients (92.4%) had an indwelling central venous catheter. G-CSF was individually administered in some patients, but was not a study objective in this clinical trial. Most patients (82.9%) were receiving thrice-weekly prophylaxis for Pneumocystis carinii with thrimethroprim-sulfamethoxazole.
Treatment
All patients were treated according to the clinical trial AML-BFM 93. 7 Briefly, the patients were randomized at diagnosis to receive the 8- Children with Down syndrome were treated according to the protocol AML-BFM 93, but were not included as protocol patients in the clinical trial AML-BFM 93. Until 1996, most patients with Down syndrome received the same therapy as patients without Down syndrome. However, in October 1996, the intensity of chemotherapy was reduced in patients with Down syndrome because of the high toxicity: HAM was omitted and the dosage of anthracyclines was reduced to two-thirds of the original dosage. 8 For all patients, intensification was given with one block of high-dose cytarabine and etoposide (HAE). Intensive treatment was followed by cranial irradiation and maintenance therapy for a total of 18 months.
Statistical analysis
The anonimyzed patients' data were collected using Microsoft Access (version 2000 for Windows 95/NT). The comparison of different groups was performed using a w 2 test or Fisher's exact test, when applicable. The P-values reported are two-tailed, and P-values less than 0.05 were considered to be significant. All statistical calculations were carried out with the statistical software package BiAS (version 7.07 for Windows 95/NT).
Results
Overall, 304 patients (165 boys, 139 girls) treated according to the clinical trial AML-BFM 93 were reviewed. In all, 28 of the patients were diagnosed with Down syndrome. These 28 patients constituted 51.9% of all the 54 patients with Down syndrome treated according to the trial AML-BFM 93; however, patients with Down syndrome were not officially enrolled as protocol patients. In contrast, the 276 patients without Down syndrome represented 58.6% of all 471 patients officially registered as protocol patients in the clinical trial AML-BFM 93. In total, 30 centers were included in the analysis (4-23 patients per center). The median age of the patients was 5 years 10 months (range 1 month to 17 years 9 months). The distribution of FAB morphology was as follows (patients with Down syndrome excluded): 13 patients with M0, 33 with M1, 71 with M2, 14 with M3, 50 with M4/M4Eo, 64 with M5, 13 with M6, and 18 with M7. Among the 28 patients with Down syndrome, 23 patients had M7 morphology, two patients could not be classified, and one patient each had M3, M5, and M6 morphology. In all, 90 patients were treated according to standard risk and 186 according to high risk (early HAM and late HAM: 67 and 119 patients, respectively). Overall, 855 infections were seen in 304 patients (2.8 infectious complications per patient during intensive treatment). Out of these 855 infectious episodes, 523 (61.2%) were classified as FUO, 57 (6.7%) as clinically documented, and 275 (32.1%) as microbiologically documented ( Table 1 ). The overall findings did not differ significantly from the findings in 28 patients with Down syndrome (FUO 34/68 infectious episodes (50%), clinically and microbiologically documented infections 6/68 (8.8%), and 28/68 infectious episodes (41.2%), respectively). Neutropenia was present in almost three-quarters of infectious episodes (634 episodes (74.1%)), but the distribution of FUO, clinically, and microbiologically documented infections did not differ between neutropenic and non-neutropenic episodes (59.8, 5.7, and 34.5%, and 65.2, 9.5, and 25.3%, respectively) (data not shown). Only three patients experienced no single infectious episode. Out of the 304 patients, 55 had one infectious episode, 70 patients suffered from two infections, 84 from three, 61 from four, 24 from five, five from six, and two from seven infections. When analyzing the first, the second up to the seventh infectious episode, the distribution of FUO, clinically, and microbiologically documented infections did not differ from the overall distribution.
Bloodstream infections occurred in 228 out of the 275 microbiologically documented infections. In 24 episodes (10.5%), more than one pathogen was recovered. Of a total of 252 isolates, 203 (80.6%) were Gram-positive and 49 (19.4%) were Gram-negative ( Table 2) . Out of a total of 203, 163 Grampositive organisms (80.3%) and 42 (85.7%) out of a total of 49 Gram-negative organisms were recovered in neutropenic patients, whereas 40 Gram-positive (19.7%) and seven Gramnegative organisms (14.3%) were isolated in non-neutropenic Table 1 Classification of infectious episodes according to chemotherapy Infections in children undergoing therapy for AML T Lehrnbecher et al patients ( Table 2 ). The incidence of Gram-positive and Gramnegative bacteremia did not differ significantly between the cycles of chemotherapy, whereas the incidence of sepsis due to viridans group streptococci (VGS) was significantly higher in cycles of chemotherapy that included high-dose cytarabine (31 episodes of sepsis due to VGS out of 358 cycles of HAM or HAE (8.7%) vs 25 episodes of sepsis due to VGS out of 550 cycles of induction/consolidation (4.6%) (P ¼ 0.027)). Whereas the proportion of Gram-negative organisms showed a great variation with a peak of 29.2% in 1996 and a nadir of 12.8% in 1997, the incidence of infections due to VGS remained stable throughout the study period (21-24%).
In 113 out of the 855 infectious episodes (13.3%), pneumonia was radiologically diagnosed (Table 3) . Pneumonia occurred significantly more often during induction therapy compared to the other cycles of chemotherapy (P ¼ 0.0007). In 14 out of these 113 episodes, a pathogen was recovered in the bloodstream (CoNS (2), VGS (4), Gram-negative organisms (8)). In another 24 patients, sputum culture was positive for a possible pathogen for pneumonia (Staphylococcus aureus (one), VGS (9), Enterococci (2), Corynebacterium spp (1), Haemophilus influenzae (2), Klebsiella spp (2), Escherichia coli (1), Enterobacter spp (4), and respiratory syncytial virus (2)). Pulmonary aspergillosis was proven in five patients and suspected in another five children, whereas invasive candidiasis was proven in two and suspected in three patients (Table 4) . Four patients suffered from meningitis caused by Streptococcus sanguis (1), Propionibact spp (2), and Acinetobacter spp (1), one patient from urinary tract infection caused by Enterococcus spp. S. aureus was recovered from an abscess in one patient. A causative organism of diarrhea was identified in the stool of 43 patients (C. difficile (26), rotavirus (14) , Salmonella spp (2), and adenovirus (1)), whereas viral infection with cytomegalovirus was seen in four patients, and infection due to herpes simplex virus in one patient.
Overall, 20 out of the 304 patients (6.6%) died because of infection-associated complications (Table 5) . No trend of mortality was observed throughout the study period. Compared to children without Down syndrome, patients with Down syndrome were significantly over-represented among children with infection-associated fatal complications (5/28 (17.9%) vs (1), and Bramhanella spp (1). CoNS coagulase-negative staphylococci, VGS viridans group streptococci.
Table 3
Sites of infection according to chemotherapy (Table 5 ). In all, 11 patients (55.0%) died due to infections within the first 6 weeks after diagnosis. In total, 18 patients (90.0%) had radiologic signs of pneumonia. Streptococci were recovered from four patients, Gram-negative organisms from five patients, and invasive Aspergillosis was proven in four patients (Table 5) . Notably, six out of nine patients, who died during HAM or consolidation, had not reached complete remission.
Discussion
Infectious complications are a major cause for morbidity and mortality in patients undergoing therapy for cancer. Hematologic malignancies, in particular AML, are associated with more infections than solid tumors. [2] [3] [4] 9 Comparable to our findings, other authors report that pediatric and adult patients undergoing various intensive treatments for AML experience an average number of three infectious episodes throughout therapy and that less than 3% of all patients remain without any infectious complication. 3, 4, 10 In contrast, the reported infection-related mortality varied between 5 and 31%, which might be explained by different age groups, different treatment regimens, and different supportive care strategies (Feusner et al. Blood 2002; 100: 332a; abstract). 3, 10 We observed that roughly threequarters of infections occurred during severe neutropenia, which is considered as a sentinel risk factor for the development of serious infections. 4, 11 On the other hand, one-quarter of patients experienced infections without a significant loss of neutrophils, underlining the importance of therapy-induced alterations of other arms of the immune system, such as lymphocytes, natural killer cells, or innate immunity. 12 Although Gram-positive organisms represented the majority of bloodstream isolates, we did not find an increasing incidence of Gram-positive isolates throughout the study period, as recently reported by Wisplinghoff et al. 5 This study, however, focused on adult patients with a wide variety of underlying malignancies, whereas we looked at children with AML. CoNS and VGS accounted for more than half of Gram-positive bloodstream isolates (67%), which is consistent with previous reports (Feusner et al. Blood 2002; 100: 332a; abstract). 4 The incidence of VGS was significantly higher after therapeutic regimens that included high-dose cytarabine (P ¼ 0.027). Furthermore, VGS bacteremia occurred more often during episodes of neutropenia (49/205 (23.9%) vs 7/47 (14.9%) in non-neutropenic episodes), although the difference did not reach statistical significance. Both treatment with high-dose cytarabine and severe neutropenia have been implicated to predispose individuals to develop VGS bacteremia. 13 Other risk factors for VGS bacteremia, however, such as the use of colistin or female sex, were not associated in our analysis with a higher incidence of VGS. 13, 14 Unfortunately, it was not possible to determine the role of antimicrobial prophylaxis in the development of VGS sepsis, since most of the children received trimethroprim-sulfamethoxazole, whereas fluoroquinolones were rarely administered. In contrast to other reports, 13, 15 we did not find an increasing incidence of VGS, which is probably due to the fact that modalities of cytotoxic therapy and supportive care remained unchanged throughout the study period. Notably, prophylaxis with penicillin was not routinely recommended at that time. Acute respiratory distress syndrome has been observed in VGS sepsis in as many as 25% of patients, 16 whereas in our population only four out of 56 patients with VGS (7.1%) had to be ventilated. This might reflect the early initiation of appropriate therapy.
Gram-negative organisms accounted for only 49 out of 252 bloodstream isolates (19.4%). Similar results were reported by Feusner et al. (Blood 2002 ; 100: 332a; abstract), whereas in an early study, Woods et al 17 observed an equal incidence of Gram-positive and Gram-negative sepsis in children with AML. The difference might be explained, at least in part, by the shift towards Gram-positive organisms over the last decade, which in turn is due to factors such as the wide use of indwelling central catheters. 18 Corroborating previous reports, Pseudomonas aeruginosa, E. coli, and Klebsiella spp were the predominant isolates among the Gram-negative organisms in our analysis (63.3%) (Feusner et al. Blood 2002 ; 100: 332a; abstract). 3 Interestingly, 42 out of the 49 Gram-negative isolates (85.7%) were found during episodes of neutropenia. Eight out of these 42 patients (19%) had to be ventilated and/or experienced septic shock, reflecting the high pathogeneity of these organisms.
It is important to note that the lung was the second most common site of infection. In contrast to children with solid tumors, a high incidence of lower respiratory tract infections has been observed in children with hematologic malignancies. 3, 4, 9 We are unable to explain why pneumonia significantly occurred more often during induction therapy compared to other cycles of therapy.
We recognize that the low frequency of probable or proven fungal infections most likely represents an underestimation of the true incidence and might reflect insufficient diagnostic procedures, such as a low number of imaging studies (data not shown). On the other hand, we applied rather stringent criteria defining invasive fungal infections, 6 whereas the definitions used by other authors are not detailed and might account for a higher incidence of invasive mycoses (Feusner et al. Blood 2002; 100: 332a; abstract). 19 Unlike patients undergoing bone marrow or stem cell transplantation, children receiving chemotherapy for AML are not routinely tested for viral infections during febrile neutropenic episodes. Therefore, the low incidence of viral infection in our study population is not surprising.
The overall infection-related mortality of 6.6% was comparable to two recent studies (Feusner et al. Blood 2002 ; 100: 332a; abstract). 10 However, neither of these two studies included patients with Down syndrome in the analysis, whereas in our study, patients with Down syndrome constituted five out of the 20 infection-associated deaths. Zubizarreta et al 20 reported on a particular high toxicity of intensive chemotherapy in children with AML and Down syndrome; six of the 11 patients died of sepsis or pulmonary infection. On the other hand, myeloblasts from children with Down syndrome and AML have increased in vitro sensitivity to cytarabine and daunorubicine. 21 Therefore, since October 1996, patients with Down syndrome treated according to the clinical trials AML-BFM 93 and AML-BFM 98 received anthracyclines in a reduced dosage and consolidation without HAM. According to preliminary data, this strategy results in a better outcome in patients with Down syndrome compared with treatment strategies with palliative or very intensive chemotherapeutic regimens (manuscript in preparation). It has to be speculated whether in a subgroup of patients, an improved overall survival can be achieved by a reduction of the intensity of chemotherapy. On the other hand, better strategies of supportive care might help to improve overall survival in children with AML. According to preliminary results of the national Phase III study CCG-2961, the institution of improved infection management strategies significantly lowered the nonleukemic deaths (Feusner et al. Blood 2002 ; 100: 332a; abstract).
In conclusion, infection-associated morbidity and mortality of children undergoing chemotherapy for AML is substantial. Therefore, children with AML should be treated in specialized pediatric cancer centers, and there should be a very low threshold to readmit patients, including not only those who are febrile but also those who have nonspecific symptoms, in particular regarding the lung. Further considerations have to include the prophylactic use of antifungal agents, the improvement of diagnostic procedures in suspected invasive fungal disease, and the empirical use of vancomycin in children with fever and neutropenia, all of which will be implemented in the new clinical multicenter trial AML-BFM 2003.
